Search clinical trials for: severe Rheumatoid Arthritis

Total 19232 results

Teva Pharmaceutical Industries, Ltd.

Completed

TL011 in Severe, Active Rheumatoid Arthritis Patients

Rheumatoid Arthritis

Czechia, Hungary, Italy, Spain, United Kingdom
AbbVie

Completed

A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)

Rheumatoid Arthritis (RA)

Brazil, China, Korea, Republic of
Universidad Nacional de Colombia

Completed

Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye

Dry Eye | Sjogren Syndrome
AbbVie

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA)

United States, Germany, Hungary, Israel, Netherlands, Poland, Puerto Rico
GlaxoSmithKline

Completed

Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)

Arthritis, Rheumatoid

Spain, Germany, Russian Federation, United Kingdom, Italy, Poland
Gilead Sciences
Galapagos NV

Completed

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (FINCH 1)

Rheumatoid Arthritis

United States, Italy, Poland, Ukraine, Belgium, Hong Kong, Taiwan, Spain, Israel, Bulgaria, India, Serbia, South Africa, Korea, Republic of, Japan, Russian Federation, Argentina, Germany, New Zealand, Thailand, Hungary, Netherlands, Slovaki... and more
Gilead Sciences
Galapagos NV

Completed

Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy (FINCH 3)

Rheumatoid Arthritis

United States, Italy, Poland, Ukraine, Belgium, Hong Kong, Taiwan, Spain, Bulgaria, India, Malaysia, Romania, Serbia, South Africa, Korea, Republic of, Japan, Australia, Chile, Russian Federation, Argentina, Germany, New Zealand, Th... and more
CSL Behring

Completed

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Italy, United States, France, Argentina, Mexico, Japan, Canada, Hungary, South Africa
Epitech Mag Ltd.

Terminated

Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease (OMNS)

Dry Eye Syndromes | Sjogren's Syndrome | ATD

Israel
SecuraBio

Completed

A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone (ASPIRA)

Rheumatoid Arthritis

Poland, Ukraine, Mexico, Bulgaria, Romania, Serbia, New Zealand, Russian Federation, Germany, Hungary, Colombia
GlaxoSmithKline

Completed

Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis

Arthritis, Rheumatoid

Ukraine, Bulgaria, Canada, Czechia, Estonia, Germany, Hungary, Italy, Mexico, Poland, Russian Federation, South Africa, Spain, United Kingdom
Eisai Korea Inc.

Completed

Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World (HUMAN)

Arthritis, Rheumatoid

Korea, Republic of
University of California, Los Angeles

Completed

Long-term Observation of Patients With Early Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Amgen

Completed

Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to Rituximab

Arthritis, Rheumatoid

United States, Germany, Bulgaria, Hungary, Poland, Estonia
Genentech, Inc.

Completed

A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350

Rheumatoid Arthritis

United States, Serbia, Bulgaria, Ukraine, Poland, Russian Federation, Argentina, Brazil, Colombia, Mexico
Shanghai Biomabs Pharmaceutical Co., Ltd.

Completed

CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid Arthritis

China
Hoffmann-La Roche

Terminated

A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy

Rheumatoid Arthritis

Spain, United Kingdom, United States, Italy, Peru, Argentina, Colombia, Mexico, Germany, Austria, Guatemala
Dr. Reddy's Laboratories Limited

Completed

Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

India, Ukraine
JHL Biotech, Inc.

Terminated

A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis

Arthritis, Rheumatoid | Rheumatoid Arthritis

Bosnia and Herzegovina, Bulgaria, Czechia, Germany, Hungary, Lithuania, Poland, Russian Federation, Taiwan, Ukraine, United Kingdom
Chong Kun Dang Pharmaceutical

Completed

A Study Evaluating the Efficacy and Safety of CKD-506 in Adult Subjects With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate

Rheumatoid Arthritis

Czechia, Georgia, Poland, Russian Federation, Ukraine
Fresenius Kabi SwissBioSim GmbH

Completed

MSB11022 in Moderate to Severe Rheumatoid Arthritis (Auriel-RA)

Moderate to Severe Rheumatoid Arthritis

Bulgaria, United Kingdom, Hungary, Czechia, Poland, Germany
Hoffmann-La Roche

Completed

A Non-Interventional Study in Patients With Moderate to Severe Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)

Rheumatoid Arthritis

Estonia
UCB Biopharma S.P.R.L.

Completed

Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Moderate and Severe Active Rheumatoid Arthritis | Active Psoriatic Arthritis | Active Ankylosing Spondylitis | Moderately to Severely Active Crohn's Disease

United States
Eli Lilly and Company

Completed

A Study in Participants With Moderate to Severe Rheumatoid Arthritis (RA-BEGIN)

Rheumatoid Arthritis

United States, Argentina, India, Korea, Republic of, Puerto Rico, Italy, Belgium, Canada, Japan, Mexico, Russian Federation, United Kingdom, Germany, Portugal, Greece, South Africa, Brazil, Austria, Sweden
Eli Lilly and Company

Completed

A Study in Moderate to Severe Rheumatoid Arthritis Participants (RA-BUILD)

Rheumatoid Arthritis

United States, India, Hungary, Puerto Rico, Romania, Poland, Belgium, Canada, Russian Federation, Spain, Japan, Argentina, Croatia, Australia, Taiwan, Italy, Czechia, Mexico, Korea, Republic of, United Kingdom, Slovakia, Germany, Po...
Eli Lilly and Company

Completed

A Moderate to Severe Rheumatoid Arthritis Study (RA-BEACON)

Rheumatoid Arthritis

United States, Israel, Turkey, Spain, Puerto Rico, Germany, Italy, France, Japan, Mexico, United Kingdom, Austria, Denmark, Poland, Australia, Greece, Switzerland, Argentina, Korea, Republic of, Belgium, Canada, Netherlands
Eli Lilly and Company

Completed

A Study in Moderate to Severe Rheumatoid Arthritis (RA-BEAM)

Rheumatoid Arthritis

Argentina, Korea, Republic of, United States, Spain, China, Hungary, Romania, Poland, Belgium, Czechia, France, Japan, Mexico, Russian Federation, United Kingdom, Puerto Rico, Portugal, Greece, Taiwan, Latvia, South Africa, Canada, ... and more
Amgen

Completed

Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab

Arthritis, Rheumatoid

United States, Spain, Australia, Bulgaria, Germany, Poland, Canada, Czechia, Hungary
Astellas Pharma Inc

Completed

A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects

Arthritis, Rheumatoid

Japan
Astellas Pharma Global Development, Inc.

Completed

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Poland, Czechia, Bulgaria, Hungary, Mexico
Astellas Pharma Inc

Completed

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate

Arthritis, Rheumatoid

United States, Poland, Colombia, Belgium, Czechia, Bulgaria, Hungary, Mexico
Bristol-Myers Squibb

Completed

Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Japan, Spain, United States, Mexico, Italy, Poland, France, Brazil, Korea, Republic of, Canada, Taiwan, Russian Federation, South Africa, Argentina, Germany, Austria, Netherlands
Hoffmann-La Roche

Completed

A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Brazil
Hoffmann-La Roche

Completed

An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)

Rheumatoid Arthritis

Netherlands
RemeGen Co., Ltd.

Terminated

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

Moderate and Severe Rheumatoid Arthritis

China
Takeda

Terminated

Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate (TELLUS)

Rheumatoid Arthritis

Spain, Estonia, Russian Federation, Czechia, United Kingdom
Bristol-Myers Squibb

Completed

Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC) (ABC)

Rheumatoid Arthritis

Canada
Takeda

Completed

Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) (NEXUS)

Rheumatoid Arthritis

Poland, Spain, Bulgaria, Russian Federation, Czechia, Japan, Korea, Republic of, United Kingdom
Pontificia Universidad Catolica de Chile
Hospital Dr Sotero del Rio

Unknown

Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye

Dry Eye | Keratoconjunctivitis Sicca | Lacrimal Apparatus Diseases | Conjunctival Diseases | Keratitis | Corneal Diseases | Sjogren's Syndrome

Chile
UCB Pharma SA
Parexel

Completed

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Rheumatoid Arthritis

Romania, United States, Australia, Austria, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Ireland, Italy, Mexico, Monaco, Poland, Portugal, Spain, Switzerland, United Kingdom
Gilead Sciences

Terminated

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Momenta Pharmaceuticals, Inc.

Completed

Usability of an AI for M923 in Subjects With Moderate to Severe RA

Rheumatoid Arthritis

United States
Hoffmann-La Roche

Completed

A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs

Rheumatoid Arthritis

Portugal
Hoffmann-La Roche

Completed

A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs.

Rheumatoid Arthritis

Russian Federation
Hoffmann-La Roche

Completed

A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

Lebanon, Kuwait, Qatar, United Arab Emirates
Oscotec Inc.
PPD

Completed

Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers

Rheumatoid Arthritis

United States
Hoffmann-La Roche

Terminated

A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Poland
Amgen

Terminated

Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab (ROCkIES)

Moderate to Severe Rheumatoid Arthritis

United States, Canada, Puerto Rico
Sanofi
Regeneron Pharmaceuticals

Completed

A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)

Rheumatoid Arthritis

Japan
Boehringer Ingelheim

Terminated

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Belgium, Bulgaria, Germany, Greece, Netherlands, Poland, Portugal, Spain

Search clinical trials for: severe Rheumatoid Arthritis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations